Clinical Pharmacokinetics

, Volume 27, Issue 4, pp 256–269 | Cite as

Clinical Pharmacokinetics of Paclitaxel

  • Daryl S. Sonnichsen
  • Mary V. Relling
Review Article Drug Disposition


Paclitaxel is a new anticancer agent showing significant promise as therapy for solid tumours and leukaemia, given alone or in combination with other chemotherapeutic agents. Paclitaxel concentrations in biological specimens can be measured using high performance liquid chromatography, or more recently by immunoassay.

Pharmacokinetic studies in which adults have been administered paclitaxel intravenously over 1 to 96 hours have demonstrated the following pharmacokinetic characteristics: extensive tissue distribution; high plasma protein binding (approximately 90 to 95%); variable systemic clearance, with average clearances ranging from 87 to 503 ml/min/m2 (5.2 to 30.2 L/h/m2); and minimal renal excretion of parent drug (<10%). In vitro and in vivo studies have demonstrated that paclitaxel is extensively metabolised by the liver to 3 primary metabolites. Cytochrome P450 enzymes of the CYP3A and CYP2C subfamilies appear to be involved in hepatic metabolism of paclitaxel.

Although early reports suggested that paclitaxel has first-order pharmacokinetics, some recent trials in children and adults suggest that its elimination is saturable. The clinical importance of saturable elimination would be greatest when large dosages are administered and/or the drug is infused over a shorter period of time. In these situations, achievable plasma concentrations are likely to exceed the affinity constant for elimination (Km). Thus, small changes in dosage or infusion duration may result in disproportionately large alterations in paclitaxel systemic exposure, potentially influencing patient response.

A pharmacokinetic analysis of the combination of cisplatin and paclitaxel has demonstrated that paclitaxel clearance is apparently sequence dependent. Patients administered cisplatin prior to paclitaxel had lower clearances and greater clinical toxicity than patients receiving paclitaxel before cisplatin. Additional pharmacodynamic analyses have shown nonhaematological and haematological toxicity to correlate better with parameters of paclitaxel exposure (e.g. area under the plasma concentration-time curve, duration of plasma concentrations exceeding 0.1 µmol/L) than with the administered dosage.


Paclitaxel Adis International Limited Clin Oncol Taxol Systemic Clearance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Schiff P, Fant J, Horwitz S. Promotion of microtubule assembly in vitro by taxol. Nature 1979; 277: 665–7PubMedCrossRefGoogle Scholar
  2. 2.
    Manfredi J, Parness J, Horwitz S. Taxol binds to cellular microtubules. J Cell Biol 1982; 94: 688–96PubMedCrossRefGoogle Scholar
  3. 3.
    Rowinsky E, Cazenave L, Donehower R. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 1990; 82: 1247–59PubMedCrossRefGoogle Scholar
  4. 4.
    Rowinsky E, Donehower R, Jones R, et al. Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res 1988; 48: 4093–100PubMedGoogle Scholar
  5. 5.
    Roberts J, Allison D, Donehower R, et al. Development of polyploidization in taxol-resistant human leukemia cells in vitro. Cancer Res 1990; 50: 710–6PubMedGoogle Scholar
  6. 6.
    Jachez B, Nordmann R, Loor F. Restoration of taxol sensitivity of multidrug-resistant cells by the cyclosporin SDZ PSC 833 and the cyclopeptolide SDZ 280–446. J Natl Cancer Inst 1993; 85: 478–83PubMedCrossRefGoogle Scholar
  7. 7.
    Chervinsky D, Brecher M, Hoelcle M. Cremophor-EL enhances taxol efficacy in a multi-drug resistant C1300 neuroblastoma cell line. Anticancer Res 1993; 13: 93–6PubMedGoogle Scholar
  8. 8.
    Parness J, Kingston D, Powell R, et al. Structure-activity study of cytotoxicity and microtubule assembly in vitro by taxol and related taxanes. Biochem Biophys Res Commun 1982; 105: 1082–9PubMedCrossRefGoogle Scholar
  9. 9.
    Waugh W, Trissel L, Stella V. Stability, compatibility, and plasticizer extraction of taxol (NSC-125973) injection diluted in infusion solutions and stored in various containers. Am J Hosp Pharm 1991; 48: 1520–4PubMedGoogle Scholar
  10. 10.
    Rizzo J, Riley C, Von Hoff D, et al. Analysis of anticancer drugs in biological fluids: determination of taxol with application to clinical pharmacokinetics. J Pharm Biomed Anal 1990; 8: 159–64PubMedCrossRefGoogle Scholar
  11. 11.
    Longnecker S, Donehower R, Cates A, et al. High-performance liquid Chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial. Cancer Treat Rep 1987; 71: 53–9PubMedGoogle Scholar
  12. 12.
    Wiernik P, Schwartz E, Strauman J, et al. Phase I clinical and pharmacokinetic study of taxol. Cancer Res 1987; 47: 2486–93PubMedGoogle Scholar
  13. 13.
    Grem J, Tutsch K, Simon K, et al. Phase I study of taxol administered as a short IV infusion daily for 5 days. Cancer Treat Rep 1987; 71: 1179–84PubMedGoogle Scholar
  14. 14.
    Jamis-Dow C, Klecker R, Sarosy G, et al. Steady state plasma concentrations and effects of taxol for a 250 mg/m2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer. Cancer Chemother Pharmacol 1993; 33: 48–52PubMedCrossRefGoogle Scholar
  15. 15.
    Huizing T, Keung A, van der Kuij V, et al. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 1993; 11: 2127–35PubMedGoogle Scholar
  16. 16.
    Schiller J, Storer B, Tutsch K, et al. Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol 1994; 12: 241–8PubMedGoogle Scholar
  17. 17.
    Sonnichsen D, Hurwitz C, Pratt C, et al. Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J Clin Oncol 1994; 12: 532–8PubMedGoogle Scholar
  18. 18.
    Wiernik P, Schwartz E, Einzig A, et al. Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol 1987; 5: 1232–9PubMedGoogle Scholar
  19. 19.
    Leu J, Chen B, Schiff P, et al. Characterization of polyclonal and monoclonal anti-taxol antibodies and measurement of taxol in serum. Cancer Res 1993; 53: 1388–91PubMedGoogle Scholar
  20. 20.
    Grothaus P, Raybould T, Bignami G, et al. An enzyme immunoassay for the determination of taxol and taxanes in Taxus sp. tissues and human plasma. J Immunol Method 1993; 158: 5–15CrossRefGoogle Scholar
  21. 21.
    Markman M, Rowinsky E, Hakes T, et al. Phase I trial of intraperitoneal taxol: a gynecologic oncology group study. J Clin Oncol 1992; 10: 1485–91PubMedGoogle Scholar
  22. 22.
    Brown T, Havlin K, Weiss G, et al. A phase I trial of taxol given by a 6-hour intravenous infusion. J Clin Oncol 1991; 9: 1261–7PubMedGoogle Scholar
  23. 23.
    Rowinsky E, Burke P, Karp J, et al. Phase I and pharmacodynamic study of taxol in refractory acute leukemias. Cancer Res 1989; 49: 4640–7PubMedGoogle Scholar
  24. 24.
    Monsarrat B, Mariel E, Cros S, et al. Taxol metabolism, isolation and identification of three major metabolite of taxol in rat bile. Drug Metab Dispos 1990; 18: 895–901PubMedGoogle Scholar
  25. 25.
    Walle T, Kumar G, McMillan J, et al. Taxol metabolism in rat hepatocytes. Biochem Pharmacol 1993; 46: 1661–4PubMedCrossRefGoogle Scholar
  26. 26.
    Monsarrat BM, Alvineric P, Wright M, et al. Hepatic metabolism and biliary excretion of taxol in rats and humans. Monogr Natl Cancer Inst 1993; 15: 39–46PubMedGoogle Scholar
  27. 27.
    Cresteil T, Monsarrat B, Alvinerie P, et al. Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res 1994; 54: 386–92PubMedGoogle Scholar
  28. 28.
    Klecker R, Jamis-Dow C, Egorin M, et al. Effect of cimetidine, probenecid, and ketoconazole on the distribution, biliary secretion, and metabolism of [3H]taxol in the Sprague-Dawley rat. Drug Metab Dispos 1994; 22: 254–8PubMedGoogle Scholar
  29. 29.
    Gianni L, Kearns C, Giani A, et al. Nonlinear pharmacokinetics, metabolism and pharmacodynamics of paclitaxel in adult patients with solid tumors. J Clin Oncol. In pressGoogle Scholar
  30. 30.
    Rowinsky E, Gilbert M, McGuire W, et al. Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 1991; 9: 1692–703PubMedGoogle Scholar
  31. 31.
    Arbuck S. Paclitaxel: what schedule? what dose? J Clin Oncol 1994; 12: 233–6PubMedGoogle Scholar
  32. 32.
    Rowinsky E, Citardi M, Noe D, et al. Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine. J Cancer Res Clin Oncol 1993; 119: 727–33PubMedCrossRefGoogle Scholar
  33. 33.
    Berg S, Cowan K, Balis F, et al. Pharmacokinetics of taxol and doxorubicin administered alone and in combination by continuous 72-hour infusion. J Natl Cancer Inst 1994; 86: 143–5PubMedCrossRefGoogle Scholar
  34. 34.
    Seibel N, Ames M, Ivy P, et al. Phase I and pharmacokinetic trial of taxol as a continuous 24 hour infusion in refractory leukemia in children [abstract]. Proc Am Soc Clin Oncol 1993; 12(381): 145Google Scholar
  35. 35.
    Hurwitz C, Relling M, Weitman S, et al. Phase I trial of paclitaxel in children with refractory solid tumors: a Pediatric Oncology Group study. J Clin Oncol 1993; 11: 2324–9PubMedGoogle Scholar
  36. 36.
    Marsoni S, Ungerleider R, Hurson S, et al. Tolerance to antineoplastic agents in children and adults. Cancer Treat Rep 1985; 69: 1263–9PubMedGoogle Scholar
  37. 37.
    Jekunen A, Christen R, Shalinsky D, et al. Synergistic interactions between cisplatin and taxol in human ovarian carcinoma cells in vitro. Br J Cancer 1994; 69: 299–306PubMedCrossRefGoogle Scholar
  38. 38.
    Rowinsky E, Chaudhry V, Forastiere A, et al. Phase I and pharmacologie study of paclitaxel and cisplatin with granulocyte colony stimulating factor: neuromuscular toxicity is dose limiting. J Clin Oncol 1993; 11: 2010–20PubMedGoogle Scholar
  39. 39.
    Kerr D, Graham J, Cummings J, et al. The effect of verapamil on the pharmacokinetics of adriamycin. Cancer Chemother Pharmacol 1986; 18: 239–42PubMedCrossRefGoogle Scholar
  40. 40.
    Erlichman C, Moore M, Theissen J, et al. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. Cancer Res 1993; 53: 4837–42PubMedGoogle Scholar
  41. 41.
    Ozols R, Willson J, Weltz M, et al. Inhibition of human ovarian cancer colony formation by adriamycin and its major metabolites. Cancer Res 1980; 40: 4109–12PubMedGoogle Scholar
  42. 42.
    Hahn S, Liebmann J, Cook J, et al. Taxol in combination with doxorubicin or etoposide; possible antagonism in vitro. Cancer 1993; 72: 2705–11PubMedCrossRefGoogle Scholar
  43. 43.
    Tischler R, Geard R, Hall E, et al. Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 1992; 52: 3495–7Google Scholar
  44. 44.
    Liebmann J, Cook J, Lipschultz C, et al. Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines. Br J Cancer 1993; 68: 1104–9PubMedCrossRefGoogle Scholar
  45. 45.
    Division of Cancer Treatment, Clinical Brochure: Taxol (IND 22850, NSC 125973). Bethesda, MD: National Cancer Institute, 1990Google Scholar
  46. 46.
    Rowinsky E, Eisenhauer E, Chaudhry V, et al: Clinical toxicities encountered with paclitaxel (Taxol®). Sem Oncol 1993; 20 Suppl. 3: 1–15Google Scholar

Copyright information

© Adis International Limited 1994

Authors and Affiliations

  • Daryl S. Sonnichsen
    • 1
    • 2
  • Mary V. Relling
    • 1
    • 2
  1. 1.Pharmaceutical DepartmentSt. Jude Children’s Research HospitalMemphisUSA
  2. 2.The Center for Pediatric Pharmacokinetics and Therapeutics, Department of Clinical PharmacyUniversity of TennesseeMemphisUSA

Personalised recommendations